NA:PHARM Pharming Group N.V

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.This company has ADRs that trade in the U.S. as the symbol PHAR.

0.83 EUR
As of 09/24/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  The Netherlands
Country of incorporation:  The Netherlands
IPO date:  10/17/2002
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   The Netherlands
Market cap:   522,300,896 EUR
Current dividend yield:   0.00%
CUSIP:    
ISIN:        NL0010391025
Sedol:      B8RC747

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy